Published in Endocrinology on October 30, 2003
Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag (2008) 1.49
Gremlin gene expression in bovine retinal pericytes exposed to elevated glucose. Br J Ophthalmol (2005) 1.15
Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway. Diabetes (2010) 1.13
Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. Br J Ophthalmol (2004) 1.05
Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes (2012) 1.05
Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia (2007) 1.03
Exercise training reduces fibrosis and matrix metalloproteinase dysregulation in the aging rat heart. FASEB J (2010) 0.97
Connective tissue growth factor is necessary for retinal capillary basal lamina thickening in diabetic mice. J Histochem Cytochem (2008) 0.95
Per2 mutation recapitulates the vascular phenotype of diabetes in the retina and bone marrow. Diabetes (2012) 0.95
Role of connective tissue growth factor in the retinal vasculature during development and ischemia. Invest Ophthalmol Vis Sci (2011) 0.94
Topically applied connective tissue growth factor/CCN2 improves diabetic preclinical cutaneous wound healing: potential role for CTGF in human diabetic foot ulcer healing. J Diabetes Res (2015) 0.91
Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int Ophthalmol (2007) 0.90
Proteolytic processing of connective tissue growth factor in normal ocular tissues and during corneal wound healing. Invest Ophthalmol Vis Sci (2012) 0.86
A mouse strain where basal connective tissue growth factor gene expression can be switched from low to high. PLoS One (2010) 0.83
Inhibition of connective tissue growth factor by small interfering ribonucleic acid prevents increase in extracellular matrix molecules in a rodent model of diabetic retinopathy. Mol Vis (2012) 0.83
Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes. Int J Mol Sci (2014) 0.82
Retinal fibrosis in diabetic retinopathy. Exp Eye Res (2016) 0.81
CCN2 expression and localization in melanoma cells. J Cell Commun Signal (2011) 0.80
CTGFsiRNA ameliorates retinal cells apoptosis in streptozotocin-induced diabetic rats. Int J Ophthalmol (2010) 0.78
Per2-Mediated Vascular Dysfunction Is Caused by the Upregulation of the Connective Tissue Growth Factor (CTGF). PLoS One (2016) 0.75
The MicroRNA-21 signaling pathway is involved in prorenin receptor (PRR) -induced VEGF expression in ARPE-19 cells under a hyperglycemic condition. Mol Vis (2017) 0.75
Connective tissue growth factor is involved in structural retinal vascular changes in long-term experimental diabetes. J Histochem Cytochem (2013) 0.75
Mesenchymal marker expression is elevated in Müller cells exposed to high glucose and in animal models of diabetic retinopathy. Oncotarget (2017) 0.75
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Insulin levels in insulin resistance: phantom of the metabolic opera? Med J Aust (2006) 5.33
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med (2008) 4.25
Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes (2008) 4.13
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Mechanisms of diabetic complications. Physiol Rev (2013) 3.41
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab (2008) 3.00
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res (2003) 2.69
Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J (2005) 2.66
Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care (2008) 2.66
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes (2007) 2.51
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes (2009) 2.34
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension (2003) 2.10
Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol (2011) 2.06
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes (2010) 1.95
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol (2005) 1.95
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol (2006) 1.88
E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes (2010) 1.85
NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation (2013) 1.78
Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res (2012) 1.78
Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation (2007) 1.74
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens (2003) 1.70
The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust (2006) 1.68
Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes (2004) 1.67
Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int (2011) 1.63
Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem (2005) 1.62
Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 1.59
Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol (2004) 1.58
Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int (2010) 1.57
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004) 1.51
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology (2002) 1.50
AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol (2007) 1.49
Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag (2008) 1.49
UKPDS and the legacy effect. N Engl J Med (2008) 1.49
TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) (2012) 1.49
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens (2002) 1.45
Change of HbA1c reporting to the new SI units. Med J Aust (2011) 1.44
Oral hypoglycaemics - a review of the evidence. Aust Fam Physician (2010) 1.43
Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. Hypertension (2012) 1.43
Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care (2013) 1.40
ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab (2004) 1.40
Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation (2009) 1.40
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens (2005) 1.40
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis (2012) 1.38
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation (2004) 1.38
ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes (2008) 1.36
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes (2002) 1.36
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol (2005) 1.35
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J (2003) 1.33
Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol (2003) 1.32
Connective tissue growth factor inhibits adipocyte differentiation. Am J Physiol Cell Physiol (2008) 1.30
The role of AGEs in cardiovascular disease. Curr Pharm Des (2008) 1.29
Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol (2004) 1.28
Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation (2002) 1.27
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care (2013) 1.26
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J (2005) 1.25
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol (2004) 1.23
Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy. Diabetes (2011) 1.22
Initiation of resuscitation with high tidal volumes causes cerebral hemodynamic disturbance, brain inflammation and injury in preterm lambs. PLoS One (2012) 1.19
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int (2004) 1.19
Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors. Diabetes Care (2008) 1.18
A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care (2002) 1.17
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol (2010) 1.16
Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol (2004) 1.15
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. Diabetes Care (2004) 1.15
Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol (2005) 1.14
Bacterial load predicts healing rate in neuropathic diabetic foot ulcers. Diabetes Care (2007) 1.14
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology (2006) 1.13
Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) (2013) 1.13
Mechanisms of diabetic nephropathy: role of hypertension. Hypertension (2006) 1.13
HGF regulates the development of cortical pyramidal dendrites. Development (2004) 1.12
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol (2008) 1.12
Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens (2010) 1.12
Connective tissue growth factor induces extracellular matrix in asthmatic airway smooth muscle. Am J Respir Crit Care Med (2005) 1.12